Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CANF 
Can Fite Biopharma Ltd ADR (CANF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CANF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.25
1 Year Target Price $7.25
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.59% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.39M USD | Price to earnings Ratio - | 1Y Target Price 7.25 |
Price to earnings Ratio - | 1Y Target Price 7.25 | ||
Volume (30-day avg) 2 | Beta 0.23 | 52 Weeks Range 0.98 - 4.69 | Updated Date 06/29/2025 |
52 Weeks Range 0.98 - 4.69 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1127.37% |
Management Effectiveness
Return on Assets (TTM) -53.18% | Return on Equity (TTM) -134.94% |
Valuation
Trailing PE - | Forward PE 2.97 | Enterprise Value 7006852 | Price to Sales(TTM) 19.87 |
Enterprise Value 7006852 | Price to Sales(TTM) 19.87 | ||
Enterprise Value to Revenue 10.4 | Enterprise Value to EBITDA 0.1 | Shares Outstanding 12877200 | Shares Floating 3105367426 |
Shares Outstanding 12877200 | Shares Floating 3105367426 | ||
Percent Insiders - | Percent Institutions 1.17 |
Analyst Ratings
Rating 2 | Target Price 7.25 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Can Fite Biopharma Ltd ADR
Company Overview
History and Background
Can-Fite BioPharma Ltd. was founded in 2000 and is an Israeli biopharmaceutical company focused on developing and commercializing novel treatments for liver, inflammatory, and autoimmune diseases. They are traded on the NYSE American as CANF.
Core Business Areas
- Liver Diseases: Development of Piclidenoson and Namodenoson for the treatment of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).
- Inflammatory Diseases: Research and development of Piclidenoson for psoriasis and rheumatoid arthritis.
Leadership and Structure
Dr. Pnina Fishman is the CEO. The company has a board of directors and various management positions overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- Piclidenoson: An A3 adenosine receptor agonist (A3AR) being developed for psoriasis and rheumatoid arthritis. It is in Phase III trials. Market share data is unavailable. Competitors include companies developing similar therapies such as Amgen (AMGN) and AbbVie (ABBV).
- Namodenoson: An A3AR agonist being developed for NASH and HCC. It is in Phase II trials. Market share data is unavailable. Competitors include Gilead Sciences (GILD) and Intercept Pharmaceuticals (ICPT) (acquired by Alfasigma).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated. It's marked by high R&D costs and lengthy clinical trials. Success depends on regulatory approvals, patent protection, and commercialization.
Positioning
Can-Fite is a smaller biopharmaceutical company focusing on A3AR agonists. Their competitive advantage lies in their proprietary technology and potential to address unmet medical needs in liver and inflammatory diseases.
Total Addressable Market (TAM)
The TAM for NASH and HCC is estimated to be billions of dollars. Can-Fite is positioned to capture a portion of this market if their drugs are approved and successfully commercialized. TAM for Psoriasis and rheumatoid arthritis also estimates in the billions.
Upturn SWOT Analysis
Strengths
- Proprietary A3AR agonist technology platform
- Promising clinical trial results for Piclidenoson and Namodenoson
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes and regulatory approvals
- Lack of established commercial infrastructure
- Relatively small size of the company
Opportunities
- Potential to partner with larger pharmaceutical companies for development and commercialization
- Expansion into new indications for A3AR agonists
- Growing market for NASH and HCC treatments
- Positive clinical trial data could attract investors
Threats
- Failure to obtain regulatory approvals
- Competition from other companies developing similar treatments
- Unfavorable clinical trial results
- Changes in the regulatory environment
- Difficulty in securing financing
Competitors and Market Share
Key Competitors
- GILD
- ABBV
- AMGN
- ICPT
Competitive Landscape
Can-Fite faces intense competition from larger, more established pharmaceutical companies. Its success depends on differentiating its products and demonstrating superior efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is primarily focused on R&D.
Future Projections: Future growth depends on the successful development and commercialization of Piclidenoson and Namodenoson. Analyst estimates vary widely and should be reviewed carefully. Growth projections are highly speculative.
Recent Initiatives: Recent initiatives include advancing Piclidenoson and Namodenoson through clinical trials, seeking partnerships, and securing financing.
Summary
Can-Fite Biopharma is a development-stage company with potential in treating liver and inflammatory diseases through its A3AR agonist technology. The company's strengths include its proprietary technology and promising clinical trial results. However, it faces challenges due to limited financial resources, reliance on clinical trial success, and competition from larger pharmaceutical companies. Can-Fite needs to focus on securing partnerships and advancing its clinical programs to drive future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, Press releases, Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available information. Clinical trial outcomes are inherently uncertain.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Can Fite Biopharma Ltd ADR
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 2012-11-06 | CEO and Chief Financial & Operating Officer Mr. Motti Farbstein | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.canfite.com |
Full time employees 5 | Website https://www.canfite.com | ||
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.